Product/Composition:- | Glibenclamide Tablets |
---|---|
Strength:- | 1.25 mg, 2.5 mg, 5 mg |
Form:- | Tablets |
Reference Brands:- | Diabeta (USA), Euglucon (EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Glibenclamide stimulates insulin secretion by binding to pancreatic β-cell sulfonylurea receptors, closing potassium channels, and triggering calcium influx. This enhances insulin release and reduces blood glucose levels. It effectively manages type 2 diabetes, especially in patients unresponsive to lifestyle changes alone, offering improved glycemic control and reduced hyperglycemic episodes.
Glibenclamide tablets, also known as glyburide in the USA, are approved for the management of type 2 diabetes mellitus. In the USA, Glibenclamide is regulated under FDA-approved monographs and primarily marketed under brands like Diabeta and Micronase. In the EU, it is authorized through national procedures and widely available under brands such as Euglucon and generics from Sandoz and Teva. Due to the increased risk of hypoglycemia, especially in elderly patients, usage guidelines emphasize dose titration and caution in renal or hepatic impairment. Pharmatradz.com facilitates B2B sourcing of Glibenclamide across regulated markets.